Hereditary Cancer Products

Similar documents
Myriad Financial Assistance Program (MFAP)

Be Ready Pack Learn more about how Myriad myrisk is revolutionizing hereditary cancer testing.

A Patient s Guide to Hereditary Cancer. Is Hereditary Cancer Testing Right for You?

GYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer

GYNplus. genetic testing for hereditary ovarian and/or uterine cancer

A guide to genetic testing for hereditary cancers

WHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.

WHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.

CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION

Assessment and Management of Genetic Predisposition to Breast Cancer. Dr Munaza Ahmed Consultant Clinical Geneticist 2/7/18

6/8/17. Genetics 101. Professor, College of Medicine. President & Chief Medical Officer. Hereditary Breast and Ovarian Cancer 2017

Objectives. Genetics in Cancer Treatment and Prevention. Genes

Primary Care Approach to Genetic Cancer Syndromes

The Next Generation of Hereditary Cancer Testing

Genetic Testing for BRCA1 and BRCA2 Genes

The benefit of. knowing. Genetic testing for hereditary cancer. A patient support guide

BRCAplus. genetic testing for hereditary breast cancer

Understanding Your Positive Result. A guide to understanding your risk and taking action

Genetic testing and pancreatic disease

Learn your genetic risk for the most common hereditary cancers.

MEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers

Genetic Testing for BRCA1 and BRCA2 Genes

Myriad Genetics Corporate Presentation 6/4/13

Hereditary Cancer Update: What do GPOs need to know?

Yes when meets criteria below. Dean Health Plan covers when Medicare also covers the benefit.

Proactive Patient Paves the Way for Genetic Testing of Eight Family Members

patient guide CancerNext genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention

Genetic Testing Today: What Genes Can Tell Us. Living Beyond Breast Cancer Conference Kara N. Maxwell, MD, PhD University of Pennsylvania

Genetic Risk Assessment for Cancer

Genetic Testing for Lynch Syndrome

Genetic Risk Assessment for Cancer

Use of panel tests in place of single gene tests in the cancer genetics clinic

Prior Authorization. Additional Information:

Genetic Testing: who, what, why?

A Patient s Guide to risk assessment. Hereditary Colorectal Cancer

Are you at risk of Hereditary Cancer? Your Guide to the Answers

Clinical Cancer Genetics

Hereditary Colorectal Cancer

Hereditary Non Polyposis Colorectal Cancer(HNPCC) From clinic to genetics

BRCA Precertification Information Request Form

Chapter 18 Section 13

Carol Christianson, MS, CGC Genetic Counselor West Michigan Cancer Center

patient guide CancerNext-Expanded genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention

Hereditary Cancer Risk Assessment for Gynecological Cancers. FarrNezhatMD.com

Expert Interview: Inherited Susceptibility to Cancer with Dr. Nicoleta Voian

Update from the 2011 symposium: MOH testing criteria

MEDICAL POLICY SUBJECT: GENETIC TESTING FOR HEREDITARY BRCA MUTATIONS. POLICY NUMBER: CATEGORY: Laboratory Test

Genetics and Cancer Care. Cynthia Forster-Gibson, MD, PhD and Loren Mackay- Loder, MSc Genetics Program, THP

Clinical Quality Assurance Measures at Myriad Genetic Laboratories:

Genetics & Precision Medicine Cancer Care

patient guide BreastNext genetic testing for hereditary breast cancer Because knowing your risk can mean early detection and prevention

Robert Nathan Slotnick MD PhD FACOG FACMG (FF) Perinatologist and Director Medical Genetics

OvaNext. patient guide. genetic testing for hereditary breast, ovarian, and uterine cancer

Hereditary Colorectal Cancer Syndromes Miguel A. Rodriguez-Bigas, MD

MEDICAL POLICY SUBJECT: GENETIC TESTING FOR INHERITED SUSCEPTIBILITY TO COLORECTAL CANCER. POLICY NUMBER: CATEGORY: Laboratory Test

Management of BRCA Positive Breast Cancer. Archana Ganaraj, MD February 17, 2018 UPDATE ON WOMEN S HEALTH

Familial and Hereditary Colon Cancer

Identification of patients suggestive of hereditary breast and ovarian cancer syndrome that warrants further professional evaluation.

GENETIC TESTING FOR HEREDITARY BREAST AND OVARIAN CANCER BRCA1 BRCA2

Genetic Testing for Familial Gastrointestinal Cancer Syndromes. C. Richard Boland, MD La Jolla, CA January 21, 2017

Disclosure. Gynecologic Cancer Genetics. Audience response. Audience response. What was the result? 47%

Lynch Syndrome (HNPCC) and MYH-Associated Polyposis (MAP)

Lynch Syndrome. Angie Strang, PGY2

Familial Adenomatous Polyposis

Predictive and Diagnostic Testing for Cancer in Women. Aparna Rajadhyaksha MD

Hereditary Breast and Ovarian Cancer Rebecca Sutphen, MD, FACMG

Genetic Testing for Hereditary Cancer Susceptibility Syndromes

GENETIC MANAGEMENT OF A FAMILY HISTORY OF BREAST AND / OR OVARIAN CANCER. Dr Abhijit Dixit. Family Health Clinical Genetics

The Role of genetic Testing for Inherited Prostate Cancer Risk

Genetic testing for hereditary cancer

HEREDITARY CANCER SYNDROMES: IDENTIFYING THOSE AT RISK


Why Test for Hereditary Cancer in Preventive Care?

HBOC. Jessica M. Salamone, ScM, CGC

Eligibility criteria for prophylactic treatment allowance

GENETIC TESTING FOR HEREDITARY CANCER

Protocols 9-12 MMR mutation carrier guidelines Frequently asked questions

Hereditary Cancer Update Strengthening Linkages Workshop April 22, 2017

Familial and Hereditary Colon Cancer

Lynch Syndrome (HNPCC) and MYH-Associated Polyposis (MAP)

Policy Specific Section: Medical Necessity and Investigational / Experimental. October 14, 1998 March 28, 2014

Germline Testing for Hereditary Cancer with Multigene Panel

GENETIC TESTING FOR HEREDITARY BREAST AND OVARIAN CANCER SYNDROME BRCA1 BRCA2

11/29/2017. Genetics and Cancer ERICA L SILVER, MS, LCGC GENETIC COUNSELOR. Genetics 101. Transcription vs Translation

Genetic Determinants, Risk Assessment and Management

Does Cancer Run in Your Family?

Page 1 of 8 TABLE OF CONTENTS

Inherited colon cancer and other inherited cancer predispositions. Dr Anne De Leener Centre de Génétique Humaine

Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes

Policy Specific Section: Medical Necessity and Investigational / Experimental. October 15, 1997 October 9, 2013

Cancer Survivorship Symposium Cancer and Heredity January 16, Jeanne P. Homer, MS Licensed Certified Genetic Counselor

Pathology reports, related operative reports and consult letters must be provided with a request for assessment.

Family Assessment. Objectives. Comprehensive Family History Important Inexpensive Underutilized genetic tool

Corporate Medical Policy

THE MODERN GYNECOLOGIC EXAMINATION & SCREENING FOR GYNECOLOGIC MALIGNANCIES

ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes

Management of higher risk of colorectal cancer. Huw Thomas

GEN ETICS AN D GEN OM ICS IN CANCER PREVENTION AN D TREATM EN T. Robert Nathan Slotnick MD PhD Director, Medical Genetics and Genomics

Transcription:

Hereditary Products Integrated BRACAnalysis (BRCA1 and BRCA2 sequencing and large rearrangement testing (BART)), covered when: PERSONAL HISTORY of Breast (must meet at least 1) Diagnosed <50 years of age no further family history needed Diagnosed with 2 or more primary breast no further family history needed cancers Diagnosed with triple negative breast no further family history needed cancer (ER-/PR-/Her2-) Diagnosed any age Ashkenazi Jewish ancestry (Multisite 3 testing only unless patient also meets criteria for Comprehensive BRACAnalysis) relative of a known BRCA mutation carrier (single-site only unless patient also meets criteria for Comprehensive BRACAnalysis) 1 st, 2 nd or 3 rd degree relative with breast cancer diagnosed <50 years of age, ovarian cancer, or bilateral breast cancer >2 1 st, 2 nd or 3 rd degree relatives with breast or pancreatic cancer at any age personal diagnosis of pancreatic cancer at any age PERSONAL HISTORY of Ovarian Diagnosed at any age no further family history needed PERSONAL HISTORY of Male Breast Diagnosed at any age no further family history needed PERSONAL HISTORY of Pancreatic Diagnosed at any age Ashkenazi Jewish ancestry (Multisite 3 testing only unless patient also meets criteria for Comprehensive BRACAnalysis) 1 st, 2 nd, or 3 rd degree relative with breast, ovarian or pancreatic cancer Breast or Ovarian Unaffected (no personal history of breast, ovarian or pancreatic cancer) relative of a known BRCA mutation carrier (single site only unless Ashkenazi Jewish, in which case Multisite3) 1 st or 2 nd degree relative who has had breast, ovarian or pancreatic cancer and who meets any of the criteria above >3 1 st, 2 nd or 3 rd degree relatives with any combination of breast, ovarian or pancreatic cancers at any age Ashkenazi Jewish ancestry and 1 st or 2 nd degree relative with breast, ovarian or pancreatic cancer at any age (Multisite 3 testing only unless patient also meets criteria for Comprehensive BRACAnalysis)

For the purposes of these criteria, the following apply: Breast cancer includes DCIS and invasive carcinoma Ovarian cancer includes peritoneal and fallopian tube cancers Ashkenazi Jewish and Central/Eastern European patients always have Multisite 3 testing rather than a single-site for one of the 3 founder mutations Pancreatic cancer refers to exocrine cancers of the pancreas NOTE: Uninsured patients who had negative BRCA1 and BRCA2 sequencing prior to May 3, 2012 and who currently meet the financial criteria for MFAP and the Integrated BRACAnalysis medical criteria are eligible to receive large rearrangement testing (BART) at no charge. A new sample, test request form and MFAP application are required.

COLARIS PLUS (MLH1, MSH2, MSH6, PMS2, MYH and EPCAM) testing covered when: PERSONAL HISTORY of Colorectal or Endometrial Diagnosed <50 years of age no further family history needed Diagnosed at any age, with MSI or IHC no further family history needed positive tumor Personal history of CRC <60 years of age no further family history needed with MSI-high histology (mucinous, signet ring, medullary growth pattern, tumor infiltrating lymphocytes, or Crohn s-like lymphocytic reaction) PERSONAL HISTORY of any Lynch Syndrome Diagnosed with a second Lynch syndrome no further family history needed cancer Diagnosed at any age 1 st or 2 nd degree relative with a Lynch syndrome cancer diagnosed at any age relative with a known MLH1, MSH2, MSH6, PMS2, MYH* or EPCAM mutation (single-site only) any Lynch Syndrome Diagnosed with >1 colorectal adenomas <40 years of age 1 st or 2 nd degree relatives with a Lynch syndrome cancer diagnosed at any age Unaffected (no personal history of any Lynch syndrome cancer) >2 1 st or 2 nd degree relatives with a Lynch syndrome cancer and 1 diagnosed <50 years of age > 3 1 st or 2 nd degree relatives with Lynch syndrome cancers at any age relative with a known MLH1, MSH2, MSH6, PMS2, MYH* or EPCAM mutation (single-site only) *Individuals who are positive for a single MYH mutation on Single Site analysis will automatically receive reflex to full MYH Analysis. Lynch syndrome cancers/tumors include the following: colorectal colon rectum endometrium/uterus ovarian small intestine/bowel duodenum jejunum gastric/stomach ureter renal pelvis sebaceous adenoma/sebaceous carcinoma glioblastoma medulloblastoma brain tumor pancreas (adenocarcinoma) biliary tract

COLARIS AP PLUS (APC and MYH analysis) covered when: PERSONAL HISTORY of > 10 colorectal adenomas Diagnosed at any age no further family history needed PERSONAL HISTORY of Colon Diagnosed at any age 1 st or 2 nd degree relative with > 10 adenomas at any age (cumulative) 1 st or 2 nd degree relative with an FAP/MAP-related tumor/clinical feature at any age relative with known APC or MYH* mutation(s) (single-site only) Diagnosed at any age with > 6 colorectal no further family history needed adenomas Diagnosed with an additional FAP/MAPrelated no further family history needed tumor/clinical feature Colorectal Adenomas or Colorectal Unaffected (no personal history) relative with known APC or MYH* mutation(s) (single-site only) >2 1 st or 2 nd degree relatives with >10 colorectal adenomas at any age (cumulative) Diagnosed with a desmoid or fibroma no further family history needed *Individuals who are positive for a single MYH mutation on Single Site analysis will automatically receive reflex to full MYH Analysis. FAP/MAP-related tumors include: desmoid fibroma epidermoid cyst osteoma CHRPE hepatoblastoma duodenal duodenal polyps ampula/periampulary/ampula of Vater

MYH Analysis* (MYH sequencing and large rearrangement analysis) covered only after Comprehensive COLARIS AP or Comprehensive COLARIS at Myriad or elsewhere when: PERSONAL HISTORY of > 10 colorectal adenomas (cumulative) Diagnosed at any age no further family history needed PERSONAL HISTORY of Colon Diagnosed <50 years of age, regardless no further family history needed of adenomas Diagnosed at any age with > 6 colorectal no further family history needed adenomas (cumulative) Colorectal Adenomas or Colorectal Unaffected (no personal history) 1 st or 2 nd degree relative with known MYH mutation(s) *MYH Analysis may be done alone or as part of COLARIS PLUS or COLARIS AP PLUS testing. MELARIS (p16) testing covered when: PERSONAL HISTORY of Melanoma Diagnosed at any age 1 st or 2 nd degree relative with melanoma at any age 1 st or 2 nd degree relative with pancreatic cancer at any age relative with a known mutation (single-site only) Diagnosed with a 2 nd primary melanoma no further family history needed Diagnosed with pancreatic cancer no further family history needed PERSONAL HISTORY of Pancreatic Diagnosed at any age 1 st or 2 nd degree relative with melanoma at any age relative with a known mutation (single-site only) Diagnosed with melanoma no further family history needed Melanoma or Pancreatic Unaffected (no personal history) relative with a known mutation (single-site only) >2 1 st or 2 nd degree relatives with melanoma 1 st or 2 nd degree relative with pancreatic cancer and 1 st or 2 nd degree relative with melanoma at any age Pancreatic cancer refers to exocrine cancers of the pancreas

PANEXIA (PALB2 sequencing and large rearrangement analysis and BRCA2 sequencing) testing covered when: PERSONAL HISTORY of Pancreatic Diagnosed at any age 1 st or 2 nd degree relative with pancreatic cancer at any age Ashkenazi Jewish ancestry (Multisite 3 testing only unless patient also meets criteria for Comprehensive PANEXIA) relative with a known mutation (single-site only, unless Ashkenazi Jewish, in which case Multisite 3 testing) Pancreatic Unaffected (no personal history) relative with a known mutation (single-site only, unless Ashkenazi Jewish, in which case Multisite 3 testing) Ashkenazi Jewish ancestry and 1 st or 2 nd degree relative with pancreatic cancer at any age (Multisite 3 testing only unless patient also meets criteria for Comprehensive PANEXIA) 2 or more 1 st or 2 nd degree relatives with pancreatic cancer at any age Reflex to p16 following Comprehensive PANEXIA is covered if the patient meets criteria for MELARIS Reflex to BRCA1 single-gene testing is covered if the patient meets criteria for Comprehensive BRACAnalysis Pancreatic cancer refers to exocrine cancers of the pancreas Reflex PALB2 single-gene testing covered when: Reflex PALB2 single gene testing is covered for any patient who has had BRACAnalysis and meets criteria for PANEXIA. Myriad myrisk Hereditary Single Site testing will be covered when: PERSONAL or NO PERSONAL HISTORY of cancer A relative with a known mutation in ATM, BARD1, BMPR1A, BRIP1, CDH1, CDK4, CDKN2A(p14ARF), CHEK2, NBN, PTEN, RAD51C, RAD51D, SMAD4, STK11, TP53 (patient would be appropriate for Single-Site testing only) Single Site testing of all other Myriad myrisk genes are included under other test offerings.

Prognostic Products Prolaris testing covered when: PERSONAL HISTORY of Prostate Patient diagnosed with prostate cancer no further family history needed Companion Diagnostic Products BRACAnalysis CDx testing covered when: PERSONAL HISTORY of Ovarian Being considered for Lynparza (olaparib) therapy no further family history needed